Enveric Biosciences, Inc. (ENVB)
NCM · Healthcare · Biotechnology
$1.42
-2.74%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$6.4M
Shares Outstanding
4.5M
Exchange
NCM
Currency
USD
About Enveric Biosciences, Inc.
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (1.9M) | (2.2M) | (1.6M) | (3.0M) |
| Net Income | (1.9M) | (2.2M) | (1.6M) | (3.0M) |
| Diluted EPS | $-10.81 | N/A | $-1.08 | $-0.76 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | ||||
| Operating Income | (20.0M) | (18.3M) | (9.6M) | (8.8M) |
| Net Income | (18.5M) | (17.3M) | (9.6M) | (8.8M) |
| Diluted EPS | $-195.00 | $-1,455.48 | $-228.48 | $-36.24 |